<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="thyroid dysfunction in children with HCV infection receiving PegIFN plus" exact="ribavirin" post="and showed that 28% of children (14 of 50)"/>
 <result pre="still widely used for treating children worldwide. Although PegIFN plus" exact="ribavirin" post="is approved for children with HCV infection (age ≥3"/>
 <result pre="virologic response rates in children with chronic hepatitis C receiving" exact="peginterferon alfa-2b" post="plus ribavirinJ Hepatol201052501720189674 5RashedYKKhalafFAKotbSEThyroid disturbances in children treated with"/>
 <result pre="and risk factors for thyroid dysfunction during peginterferon α and" exact="ribavirin" post="treatment in patients with chronic hepatitis CKorean J Intern"/>
 <result pre="https://www.hcvguidelines.org Table 1. Comparison of direct-acting antiviral and peginterferon plus" exact="ribavirin" post="in children Variable DAA PegIFN + ribavirin Administration Oral"/>
 <result pre="and peginterferon plus ribavirin in children Variable DAA PegIFN +" exact="ribavirin" post="Administration Oral PegIFN: subcutaneous injection (per week) Ribavirin: oral"/>
</results>
